NCT05004415

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-AT-527 in Healthy Adult Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Mass balance study of AT-527 in Healthy Male Subjects.

Detailed description

This is an open-label, single-dose study assessing the absorption, metabolism, excretion, and mass balance of \[14C\]-AT-527 in healthy adult male subjects.

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	AT-527 (R07496998)	Study participants will receive a single radiolabeled dose of 550 mg AT-527.

Timeline

• Start date: 2021-07-28
• Primary completion: 2021-08-12
• Completion: 2021-08-12
• First posted: 2021-08-13
• Last updated: 2022-02-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study